Personalized Drug Discovery: HCA Approach Optimized for Rare Diseases at Tel Aviv University.

Personalized Drug Discovery: HCA Approach Optimized for Rare Diseases at Tel Aviv University.
Comb Chem High Throughput Screen. 2014 Jan 9;
Authors: Solmesky LJ, Weil M
Abstract
The Cell screening facility for personalized medicine (CSFPM) at Tel Aviv University in Israel is devoted to screening small molecules libraries for finding new drugs for rare diseases using human cell based models. The main strategy of the facility is based on smartly reducing the size of the compounds collection in similarity clusters and at the same time keeping high diversity of pharmacophores. This strategy allows parallel screening of several patient derived - cells in a personalized screening approach. The tested compounds are repositioned drugs derived from collections of phase III and FDA approved small molecules. In addition, the facility carries screenings using other chemical libraries and toxicological characterizations of nanomaterials.
PMID: 24409954 [PubMed - as supplied by publisher]

Source: Combinatorial Chemistry and High Throughput Screening - January 9, 2014 Category: Chemistry Authors: Solmesky LJ, Weil M Tags: Comb Chem High Throughput Screen Source Type: research